Pacira BioSciences, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Pacira BioSciences, Inc. (Nasdaq: PCRX) develops, manufactures, commercializes and sells non-opioid pain management and regenerative health solutions primarily to healthcare practitioners in hospitals and ambulatory surgery centers in the United States. The company offers EXPAREL (bupivacaine liposome injectable suspension), a long-acting local analgesic approved for postsurgical pain management via infiltration, fascial plane block, interscalene brachial plexus nerve block, adductor canal nerve block and sciatic nerve block in the popliteal fossa; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an intra-articular injection for osteoarthritis knee pain management; iovera°, a handheld cryoanalgesia device that delivers controlled cold doses to targeted nerves for drug-free pain relief; and advances PCRX-201 (enekinragene inzadenovec), a locally administered gene therapy candidate for osteoarthritis and related musculoskeletal conditions utilizing a high-capacity adenovirus vector platform. Founded in 2006 and headquartered in Tampa, Florida, with additional facilities in Brisbane, California; Parsippany, New Jersey; San Diego, California; and international sites including Swindon, UK and Hamburg, Germany, Pacira operates as the holding company for Pacira Pharmaceuticals, Inc. and maintains a development and supply agreement with Aratana Therapeutics for NOCITA, a bupivacaine liposome injectable suspension for veterinary use. In February 2025, Pacira acquired the remaining 81% equity interest in GQ Bio Therapeutics GmbH for approximately $32 million net, building on prior investments and a manufacturing partnership to fully integrate GQ Bio's high-capacity adenovirus gene therapy platform, eliminate up to $64 million in future milestones, and accelerate innovative musculoskeletal therapies including PCRX-201, which showed sustained pain relief through two years in a Phase 1 study reported in November 2024; the company also announced new five-year objectives in October 2025 targeting over three million patients treated annually, double-digit product revenue growth, gross margin expansion and five novel pipeline programs with partnerships.
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases
Pacira Q2 Earnings & Revenues Beat, 2026 Sales Outlook Cut
Pacira BioSciences, Inc. (PCRX) Q2 2026 Earnings Call Transcript
Pacira (PCRX) Tops Q2 Earnings and Revenue Estimates
Pacira BioSciences Reports Second Quarter 2026 Financial Results
First Trust Advisors LP Grows Position in Pacira BioSciences, Inc. $PCRX
Pacira BioSciences Advances PCRX-201 Development Program with Successful Transition to Scalable Commercial Manufacturing Process
Brokerages Set Pacira BioSciences, Inc. (NASDAQ:PCRX) Price Target at $29.40
Pacira to Report Second Quarter 2026 Financial Results on Tuesday August 4, 2026
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pacira to Divest iovera Business to Zimmer Biomet in Up To $140M Deal
Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL®
Pacira BioSciences Announces Agreement to Divest its iovera° Business to Zimmer Biomet
Pacira BioSciences Announces Stockholders Have Elected All Three of the Company's Director Nominees at Annual Meeting
Pacira BioSciences, Inc. (PCRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Pacira BioSciences Reminds Stockholders to Vote the BLUE Proxy Card "FOR" the Election of the Company's Highly Qualified Nominees Ahead of its Annual Meeting
Pacira BioSciences Highlights Leading Independent Proxy Advisory Firm ISS' Recommendation to Vote "FOR" All of Pacira's Director Nominees
PharmaCorp Rx Inc. Announces First Quarter 2026 Financial Results
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Pacira's Director Nominees